you. Thank
thanks XXXX us financial and Therapeutics the for quarter third results everyone afternoon for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, Press Releases. our today, issued release under press Time with Web which site can Media found & the on section of a these
In Form our Information. Investors the & the section of XX-Q quarter XXXX Financial September XX, on addition, filed be shortly found site our Web under was thereafter for ended and can Media
the remind to management everyone except Before questions we like begin, These the results in those forward-looking forward-looking differ Private the by would of statements materially statements. statements to made on are of facts, and that historical such involve Safe under call, risks I that provisions for XXXX. actual to Act statements and of this statements conference cause responses Securities from Litigation Harbor uncertainties Reform can
Company's statements they speak the circumstances the Therapeutics placed disclaims as only filed Please the the filings SEC as on required September should forward-looking reflect Fate law, statements obligation the information, as release statements, to by the these Company's reliance future circumstances. for our the disclaimer the may included date any not update forward-looking today, on that and XXXX forward-looking are underlying XX, market ended press as with be events which today. the forward-looking these made of facts or change. to Except SEC in after see Form statement well factors Undue of in XX-Q earnings issued quarter risk the was as close
Development Vice and Bob Shoemaker, Clinical our President Valamehr, Dr. Dr. Wayne Joining me our Scientific Chief Dan our on Officer; today's of Development. Chu, are Dr. Officer Chief call
cell the data decisive has as NK past achieved the across of a T-cell product candidates established from which enable to leading milestones key series generate platform. cancer clinical Fate our Company iPSC that the off-the-shelf and the manufacturer have engineered firmly and developer immunotherapy, product Therapeutics of and Company months, Over multiple three
Fc FTXXX patient cancer immunotherapy first derived These novel, NK milestones of platform, to FTXXX. the include, our iPSC an line, one, pluripotent administered line targeted it first stem off-the-shelf iPSC induced from ever high-affinity, the express is receptor. a candidate with genetically-engineered product be non-cleavable world clonal a uniformly is from master a second cell, or product FTXXX a iPSC CDXX engineered derived is to treatment and emerging cell patient. cell in the product from to the
anti-tumor iPSC NK FTXXX, receptor, clearance Number an two, immunotherapy off-the-shelf to for chimeric uniquely that best-in-class new designed is active the cells by antigens on three tumor-associated FDA application is engage cell first engineered FDA functional ever that derived, or activity. to antigen modalities. multiple cancer expressed of express therapy drug FTXXX our CAR for is investigational cell cancer is the for investigation clinical cleared FTXXX
of therapies. And cGMP launch iPS-derived clinical for facility the of our three, manufacturer cell
within been commissioned begun drug clinical issued Our the has we the is product state-of-the-art has by renewable NK T-cell master and lines multiple custom for the a designed manufacturing the candidates qualified, off-the-shelf cell and source cell iPSC California, products. The been and allogeneic use clonal licensed manufacture State a manufacture to as of have facility. of facility of facility Company
use, established manufacture cost off-the-shelf have patients. large master to for production, effective engineer clinical genetically we With ability we believe operational iPSC our capabilities to unique delivery and industry to with proven qualified cGMP and products scale full for on-demand of control cell lines of our ensure to clonal iPSCs the combined consistent, create
activating CDXX high-affinity, is The to non line from naturally receptor antibody be coated our master is a potent cellular the on kill or receptor. mediator cell from tumor key antibody express cells. NK NK iPSC is iPSC anti-tumor recognize, dependent a bind been product ADCC, to occurring is cytotoxicity engineered with and product candidate FTXXX receptor FTXXX. Fc clonal has NK the expressed cancer of Starting a which the derived mechanism shown novel emerging cells, platform. and engineered a cleavable which first CDXX cells by immunotherapy
its most commonly which NK micro is affinity in variant form, found Fc novel contrast, its low cell CDXX in CDXX significantly to the down-regulation the In has tumor limit activity. undergo been shown receptor anti-tumor and environment, expression considerable comprised been unique to which two modified functional binding the down-regulation, to incorporated is and are variant significantly it into targeting prevent FTXXX designed is to ADCC. augment to has affinity high of enhancements; comprised enhance of it tumor form can antibodies;
is comprised trial refractory being acute for for a therapy trial The three three are refractory multi-dose who monotherapy Patients treatment X investigated relapsed are following the of the clinically CDXX study doses as of clinical first of which second myeloid doses designed FTXXX and Phase once-weekly is is relapsed to B-cell directed a activity as of combination and antibodies to treatment outpatient leukemia the of treatment safety the in clinical cycle with The once-weekly of cycle, monoclonal treatment a cycle an FTXXX eligible of FTXXX. treatment a FTXXX. stable receive assess lymphoma.
FTXXX moderate FTXXX. patient. of levels per with starting a regimen dose concurrently. treatment support cytokine at Importantly, each planned lympho million, to well promote the million cells the monoclonal XXX of million FTXXX combination activity arm cycle dose XX trial antibody XX for of safety enrolling cells dose FTXXX IL-X million Three will dose to in of AML are single XXX directed prior per CDXX evaluate anti-tumor conditioning arms patients as as clinical each are a Both with receive to and
monotherapy with refractory is October, B-cell the patient as AML of lymphoma. the B-cell a support combination established treatment the clinical and of therapy can and well of rituximab diffuse to benchmarks for against the a lymphoma, patient the safety are assess benefit antibodies of that the as FTXXX trial FTXXX believe there for large of treatment received compelling monoclonal and directed in treatment concept We with clinical treatment which in first In efficacy. of we FTXXX for AML. combination potential And CDXX for there received second proof clinical the clinical the
in setting with been direct of blast in Specifically, relapsed have bone been of have studies treated cell mediated donor-derived of shown therapy. leukemic to and NK NK patients in AML, remission derived have cell to the notably been donor particularly cell reported XX% to marrow investigator-initiated the refractory complete from therapy, NK susceptible XX% be killing rates ranging hundreds
the bone to read gain bone activity. following FTXXX marrow to anti-leukemic on and homing responses anti-leukemic to samples treatment an before addition to also the we clinical biopsies the first and FTXXX marrow cycle In early will assess dose of collect in marrow treatment to FTXXX, bone third
approved with anti-tumor monoclonal studies that therapy. In addition NK to drives activity cell have mediated demonstrated antibody tumor of killing, numerous antibodies is monoclonal targeting the direct of that an the important ADCC clinical FDA action mechanism
have treatment studies have patients with the demonstrated therapy. these monoclonal variant affinity antibody Importantly, that CDXX XXXV clinical outcomes, high for homozygous following significantly improved
DLBCL. of response have rates for However, privileged relapsed of refractory In are CDXX approximately and only antibodies XX% overall clinical rates clinical with example, single of modest form. advantaged this B-cell monoclonal in with responses, the activity agent shown response patients approximately about XX% lymphoma, XX% of setting of
augment B-cell of responses. drug is off-the-shelf XXX higher receptor enhanced variant iPSC FTXXX at that line investigation September, NK clonal down-regulation master cancer durable novel high-affinity, multi-antigen surface derived IL-XX NK and activity, proprietary the immunotherapy can Since FTXXX CDXX, targeting we receptor forefront significantly antigen resulting that A for that FTXXX. prevents we protein FTXXX non-cleavable modalities. functional and which CAR ADCC, believe engineered Fc it cell on targets a and the from active promotes a that CDXX FTXXX an expression, and more announced FDA-cleared since an cell for cancer three novel incorporates new in of immunotherapy. high-affinity anti-tumor levels cell-based fusion our In non-cleavable, application is the maintains the is with enables CAR
has the antigen It therapy active to to the clinical We antigen is and by significant engineered three patient for escape. that product That due risk candidate T-cell and to with potential allogeneic of address a cell FTXXX the is immunotherapies one components. only is recognize anti-tumor first and believe specific CARXX FDA. relapse that transformative supplant the investigation cleared fail
both Clinical of respond case the have demonstrated failure myeloma with durable antigen antigen and to CDXX against as such patient down-regulation is clearly in cells initially long-term resistance major CAR-T those to failure CAR-T mechanism of target in the BCMA leukemia CDXX a for targeted in achieve of single and experience derived that that and patients against cells even that remission. lymphoma, for BCMA respond accounts and
tumor-associated to and antigens overcome FTXXX designed is uniquely multiple CDXX antigen escape. target
expresses CDXX, of promotes a the cytokine expresses Fc with proprietary that FTXXX need in coincident therapeutic targeting IL-XX survival, CDXX complex the endogenous systemic targeting and without antigens an cytokine enables CAR FTXXX to of receptor, receptor addition the additional fusion, In antibodies. also for immune proliferation high-affinity, cells the support. combination which transactivation non-cleavable tumor-associated CDXX, potent
planned of a these exploit as of clinical cells antigen are rituximab monotherapy X in clinical million, activity functionality of to million and improved overcome first establishing cohort the dose The Upon Together, with XX to dose. escape. durability specifically potency per B-cell assess targeting response. in FTXXX per FTXXX maximize XXX is with XXX and XX million million, trial XX features cells patients safety in the designed a Phase will dose four of FTXXX combination at trial dose, intended million safety and of the multi-antigen levels, and lymphoma
combination tolerated in first lymphocytic conditioning will moderate cycle dose safety Additionally, patients which patient in will rituximab, lympho a upon FTXXX. receive in Each the outpatient clinical FTXXX, establishing prior with consists FTXXX a the of the cycle single of assess obinutuzumab to regimen the maximum combination with with chronic trial of and treatment leukemia. of activity dose
the the our based Since be of part cytokine as persistence not cytokine FTXXX in administered will observed its studies. functionality, to enhanced IL-XX FTXXX on support preclinical incorporates engineered of support patient
additional the the Importantly, treatment FDA. of patient for clinical be on patient's of by cycles review status to each evidence subject eligible of FTXXX benefit, may based
investigators have field, with clinical we CAR-T at early begun time, finalized planning multiple treatment are startup cell this we in have At sites for patient trial XXXX. the leading activities clinical the in in the and first protocol consultation of clinical
the roles indirect to NK and direct in tumors. be may solid play attacking that excited continue about they multi-faceted of We cells
inhibitor respond a types, tumor agents. therapy with these have or been therapies in and across While either checkpoint fail number progress responses curative cases, these patients solid of are most achieved not on remarkable to
can inhibitor patients evidence directly and function One class in mutations, therapy expression checkpoint into I clinical which cells of to loss with with NK to common biological of loss for the Compelling mechanism activity. genes and presentation, and critical MHC result to partial is anti-tumor resistant escape of in resistance T-cell these inhibitor antigen for associated complete or continues convert recognize checkpoint potential tumors that supports responders. from therapy emerge mutations kill
patients cell platform We believe iPSC off-the-shelf emerging candidate represents to NK re-sensitize inhibitor checkpoint resistance. novel first FTXXX therapy strategy overcome a product and potentially our to disease therapeutic product the from
the currently investigating tumors. solid clinical FTXXX X are We a trial treatment of advanced multi-dose in Phase for
doses to designed approved of with and and eligible three is total doses three or a the tumors first of of clinically additional treatment, Patients who whose up a study each of safety following the setting of response assess to in checkpoint of failed initial prior progressed to once-weekly in three monotherapy are second cycle FDA treatment combination therapies FTXXX as following doses in with respond The stable, therapy. disease for the six of checkpoint dose inhibitor FTXXX are level. inhibitor salvage receive patients activity FTXXX a once-weekly at to cycle of one
the FTXXX and States study escalation tolerability. IPS-derived cell FTXXX an dose X of first of clinical Phase trial safety is designed the product. assess ever the United Importantly, clinical trial to is The in the of stage
paradigm evaluate treatment one doses over Additionally, ever systematically it multiple where trials multiple the of is for cell to cycles. clinical are therapy administered first a novel
NK a first a cycle Finally, to escalation and first the FTXXX first off-the-shelf treatment principles To conditioning are with promote combined safety product only assessment support. receive patients of mild and the of prior to therapy. outpatient dose FTXXX, cytokine be regimen lympho universal best is cell in tolerability no inhibitor to checkpoint
rejection immunological T-cells objective A FTXXX, to and stage cell activation, immune the dose one, number including neurotoxicity and robust for immunogenicity, syndrome, two, including CDX and key patients the endogenous of evidence B-cells complete cytokine of escalation is to cytotoxic GvHD; and of T the reconstitution cells. T the three, measuring of cells; occurrence release a regulatory activity, anti-cell including; response cytokine by assessment evidence endogenous including mediated and
patients in and Phase safety have trial. dose of be arm FTXXX-related to X the We been and limiting continue treated the the study, have reported and to no three XXX million per at progress toxicities dose, million FTXXX cells date with cells dose observed been clinical adverse dose escalating pleased the five XXX with treated tolerability at per preliminary monotherapy patients of In clinical of or events. the we serious indications stage have
Additionally, million patients no prior in combination checkpoint in toxicities inhibitor cells of that is study. the in FTXXX currently XXX combination of arm combination events. have of dose dose stage reported or adverse study have with per therapy, million therapy arm three the checkpoint at the inhibitor at been dose with treated escalating trial FTXXX patients per limiting XXX failed Phase serious in Enrollment related the the ongoing the X dose clinical cells in
arm cell to into an study dose Society protocol Hematology our modifications our the expansion activity. class is of that expression the cancers level, on infiltration. combination MHC include dose cell NK induce look sharing support we of FTXXX dose Subject initial clinical experience the and NK pre-treatment clinical in expansion Meeting. most with insights to amended FTXXX amenable partial of tumors We activity to design clinical anti-tumor to or to first-in-human and the that promote our These with at clinical American the Annual trial of at to this establishing stage are forward biopsy, upcoming XXst FTXXX cytokine plans for specifically complete selecting with enriching I for of adding the plan loss only safety initiate designed based
in we University toward the platform pleased Society and function of session showcase the at Dr. therapy. end Annual Meeting well cytotoxic as checkpoint of the during advanced demonstrating as synergistic immunotherapy anti-tumor cell-based pipeline combination cells plenary compared scheduled therapy look the that present FTXXX of as will Immunotherapy NK in targeting iPS-derived activity is off-the-shelf preclinical Miller Cancer data, therapeutically the cancer Sunday be Minnesota XXXX, malignancies, meeting. Annual of innovations both As of the At Jeff Company's for of the to are we XXst NK our featured with the cell entitled iPS-derived donor-derived XXth SITC, ASH of to inhibitor cellular the and FTXXX for
B-cell including myeloma, iPS-derived immunotherapies, Dr. Memorial therapies, off-the-shelf of cellular Kettering Center, Memorial therapy T-cell Eric developing for Center, CAR-T immune Cancer multiple a be Additionally, be of adoptive annual FTXXX, in and ASH on Dr. accepted we pioneer joined unveiled collaborator steam product announce of and therapy malignancies. I expert our we Minnesota, abstracts our Sloan where morning presentation that Smith first and cell that in Kettering had which of NK am evening, cell Dr. cell tomorrow iPS-derived be and pleased to Sadelain will Sloan immunotherapy developing guests, by pioneer for event six Friday ASH, NK will hosting a of fourth Miller targeting an in CAR-T Cancer Michel collaborator at cancer cell will our our iPS-derived University we investor including of the a
treatment I want treated controlled ProTmune accomplishments study XXth of October, the the first-in-class undergoing clinical and recognize hematopoietic PROTECT ProTmune. transplantation of and manufacturing disease In enrollment we acute host to cell for graft in the is of Phase completed malignancies. team. for in patient Finally, X trial and hematopoietic the cell ProTmune the prevention randomized candidate the product versus patients patient of allogeneic double-blinded recent Company's hematologic
and look the study is GvHD from of data The following we XXXX. FDA. operational the a GvHD therapies for prevention currently seeing completion by the notable approved of of transplant. patient there allogeneic is in no morbidity the forward and achievement Company, this enrollment cause to leading early blinded acute And are mortality, for the
an the Pharmaceutical. results. quarter third cell were of our for Turning R&D with year. internal XXXX primarily candidates with to current XXXX, our derived the million Company's third-party quarter period of associated for in third iPSC-derived the financial activities Company's expenses collaboration with was the Ono with clinical headcount, development compared million and Revenue $XX.X $X.X for quarter the research the CAR-T attributable same to was under employee $XX.X to associated of the compensation with for collaboration the last associated million last and growth Revenue to and in was expenses including the million compensation, Ono in compared stock-based development and manufacture $X product increase The year. in conduct Research from period same of increase expenses expenses our Pharmaceutical.
G&A third approximately expenses attributable stock-based an compensation, to for of operating G&A increase of compared was share-based in were million. compensation. our of employee primarily non-cash for Total the of quarter compensation for expenses third million same period the including The million net XXXX $X.X XXXX, $X.X in expenses expense the year. were quarter last increase million to $X.X $XX
million September, common net In million outstanding the Company offering, was was Company convertible from XX.X ended of investments, shares with cash stock outstanding is and $XXX proceeds $XXX common million cash, short-term five which of quarter equivalents and into of the convertible completed certain million of stock XXXX third stock under the each Including shares offering. stock common conditions. preferred the shares, X.X
well pleased call with the bringing I'll of and patients to position, the And disruptive our be the cellular product across that, I And size multiple of iPSC operational questions. product up leadership and our from data immunotherapies continue Company's positioned cancer. with pursuit clinical to expanding we to progress are candidates generate open to with platform.
